Would It Be A Good Move Today To Sell ACADIA Pharmaceuticals Inc. (ACAD) Stock?

As of Friday close, ACADIA Pharmaceuticals Inc.’s (NASDAQ:ACAD) stock was up $0.82, moving up 5.25 percent to $16.44. The average number of shares traded per day over the past five days has been 2,284,600 shares. 4 times new highs have been achieved over the past 5 days, with a $1.75 gain in that time frame. In the last twenty days, the average volume was 1,821,590, while in the previous 50 days, it was 2,933,382.

Since last month, ACAD stock rose 4.65%. Shares of the company fell to $13.80 on 08/02/22, the lowest level in the past month. A 52-week high of $28.06 was reached on 04/07/22 after having rallying from a 52-week low of $12.24. Since the beginning of this year, ACAD’s stock price has dropped by -29.56% or -$6.90, and marked a new high 9 times. However, the stock has declined by -41.40% since its 52-week high.

Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now. .


ACADIA Pharmaceuticals Inc. (ACAD) last reported insider trading activity 58 days ago on Jun 09. Schneyer Mark C., the EVP, Chief Financial Officer of the company, disposed of 653 shares for $17.91 on Jun 09. It resulted in a $11,695 divestment by the insider. DAVIS STEPHEN sold 5,483 shares at an average price of $18.18 on May 02. The insider now owns 75,875 shares following the transaction. On May 02, President Stankovic Srdjan R. sold 2,865 shares at $18.18 apiece. The transaction was valued at $52,091.

Valuation Metrics

The stock’s beta is 0.71. Besides these, the trailing price-to-sales (P/S) ratio of 5.41, the price-to-book (PB) ratio of 5.96.

Financial Health

In the three months ended March 30, ACADIA Pharmaceuticals Inc.’s quick ratio stood at 4.50, while its current ratio was 4.50, showing that the company is able to pay off its debt. On the profitability front, the trailing twelve-month gross margin is 96.60% percent. In the year ended March 30, operating margins totaled -43.90%. Based on annual data, ACAD earned $473.3 million in gross profit and brought in $484.14 million in revenue.

A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was -31.60%. Return on equity (ROE) for the past 12 months was -40.50%.

According to the earnings report, the company had a lower net income in the recent quarter than it did in the previous quarter. ACAD’s revenue rose 7.72% to $130.76 million during the quarter, while net income inched up to $115.47 million. While analysts expected ACADIA Pharmaceuticals Inc. to report -$0.6 quarterly earnings, the actual figure was -$0.7 per share, beating the consensus estimate by -16.70%. During the quarter, the company generated -$112.05 million in EBITDA. The liabilities of ACADIA Pharmaceuticals Inc. were 179.45 million at the end of its most recent quarter ended March 30, and its total debt was $64.42 million. The value of shareholders’ equity is $161.43 million.

Technical Picture

This quick technical analysis looks at ACADIA Pharmaceuticals Inc.’s (ACAD) price momentum. With a historical volatility rate of 50.13%, the RSI 9-day stood at 67.73% on 05 August.

With respect to its five-day moving average, the current ACADIA Pharmaceuticals Inc. price is up by +11.91% percent or $1.75. At present, ACAD shares trade +4.45% above its 20-day simple moving average and -29.08% percent below its 100-day simple moving average. However, the stock is currently trading approximately -2.08% below its SMA50 and -6.59% below its SMA200.

Stochastic coefficient K was 77.35% and Stochastic coefficient D was 62.48%, while ATR was 0.93. Given the Stochastic reading of 83.28% for the 14-day period, the RSI (14) reading has been calculated as 59.30%. As of today, the MACD Oscillator reading stands at 0.75, while the 14-day reading stands at 0.78.

Analyst Ratings

ACADIA Pharmaceuticals Inc. downgraded its rating on ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) to a Neutral in a note to investors on August 05, 2022. The analysts firm previously had a Buy rating on the stock.ACADIA Pharmaceuticals Inc. (ACAD) has been rated Overweight by analysts. According to 1 brokerage firm, ACAD is a sell, and 12 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 0 analysts rate ACADIA Pharmaceuticals Inc. stock as buy, with 7 recommending it as overweight.

With a median target price of $20.00, the current consensus forecast for the stock is $10.00 – $27.00. Based on these forecasts, analysts predict ACADIA Pharmaceuticals Inc. (ACAD) will achieve an average price target of $21.00.


Please enter your comment!
Please enter your name here

Hot Topics

Related Articles